📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context Diabetic kidney…
Browsing: GLP-1 Receptor Agonists
Clinical trial summaries for GLP-1 receptor agonists, including cardiovascular outcomes, glycaemic control, obesity, kidney outcomes, tolerability, and practice implications.
A phase 2b randomized trial found that cotadutide reduced urinary albumin-to-creatinine ratio versus placebo in type 2 diabetes with chronic kidney disease, a surrogate signal requiring confirmation. PICO summary and expert commentary.
Design and baseline-cohort paper for the phase 3 ESSENCE trial of semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2 or 3; no efficacy outcomes are reported. PICO summary and expert commentary.
A small single-dose pharmacokinetic study found that combining insulin icodec and semaglutide into IcoSema roughly doubled semaglutide peak concentration without changing total exposure of either drug. PICO summary and expert commentary.
A post hoc analysis of a 32-week randomised trial examined how semaglutide, empagliflozin and their combination altered renal diffusion-weighted MRI and total kidney volume in type 2 diabetes. PICO summary and expert commentary.
A small mechanistic randomized trial found once-daily oral semaglutide 50 mg cut ad libitum energy intake by 39.2 percentage points versus placebo and reduced body weight, with no change in gastric emptying. PICO summary and expert commentary.
Secondary analysis of the SELECT trial finds semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes, with much of the non-cardiovascular benefit driven by fewer infectious and COVID-19-related deaths. PICO summary and expert commentary.
A secondary analysis of the pooled STEP-HFpEF trials found semaglutide improved heart-failure symptoms more in obesity-related HFpEF patients with a history of atrial fibrillation than in those without. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found once-weekly semaglutide 2.4 mg attenuated left atrial and right ventricular remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
A phase 2b randomized trial of the GLP-1/glucagon dual agonist cotadutide in type 2 diabetes and CKD, with dose-dependent reductions in albuminuria at week 14. PICO summary and expert commentary.